Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome

British Journal of Haematology

Volumn 133, Issue 6, 2006, Pages 646-648

  Al Ahmari, Ali ^a   Shah, Niketa ^a   Sung, Lillian ^a   Zipursky, Alvin ^a   Hitzler, Johann ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute megakaryoblastic leukaemia; Cytarabine; Down syndrome; Low dose chemotherapy; Treatment

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RETINOL PALMITATE; VINCRISTINE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOWN SYNDROME; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; LEUKEMIA CELL; LONGITUDINAL STUDY; LOW DRUG DOSE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARD; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYTARABINE; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; HUMANS; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; TREATMENT OUTCOME; VINCRISTINE; VITAMIN A;

EID: 33646701894     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06097.x     Document Type: Article

References (12)

1. Creutzig U. Reinhardt D. Diekamp S. Dworzak M. Stary J. Zimmermann M.D. 2005 AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity Leukemia 19 1355 1360
2. Gamis A.S. Woods W. Alonzo T. Buxton A. Lange B. Barnard D. Gold S. Smith F. 2003 Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891 Journal of Clinical Oncology 21 3415 3422
3. Ge Y. Jensen T. Stout M. Flatley R. Grohar P. Ravindranath Y. Matherly L. Taub J. 2004 The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines Cancer Research 64 728 735
4. Ge Y. Stout M. Tatman D. Jensen T. Buck S. Thomas R. Ravindranath Y. Matherly L. Taub J. 2005 GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia Journal of the National Cancer Institute 97 226 231
5. Hitzler J. Zipursky A. 2005 Origins of leukaemia in children with Down syndrome Nature Reviews. Cancer 5 11 20
6. Kudo K. Kojima S. Tabuchi K. Ishii E. Yabe H. Tawa A. Imaizumi M. Hanada R. Hamamoto K. Kobayashi R. Morimoto A. Nakayama H. Tsuchiya S. Tsuchida M. Horibe K. Tsukimoto I. 2005 Results of the Japanese childhood acute myeloid leukemia 99 protocol for Down syndrome and acute myeloid leukemia Annual Meeting of the American Society of Hematology abstract 276 84a
7. Lange B.J. Kobrinsky N. Barnard D.R. Arthur D.C. Buckley J.D. Howells W.B. Gold S. Sanders J. Neudorf S. Smith F.O. Woods W.G. 1998 Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891 Blood 91 608 615
8. Ravindranath Y. Abella E. Krischer J. Wiley J. Inoue S. Harris M. Chauvenet A. Alvarado C. Dubowy R. Ritchey A. Land V. Steuber C. Weinstein H. 1992 Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 Blood 80 2210 2214
9. Tchernia G. Lejeune F. Boccara J. Denavit M. Dommergues J. Bernaudin F. 1996 Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine Journal of Pediatric Hematology/Oncology 18 59 62
10. Zipursky A. 1996 The treatment of children with acute megakaryoblastic leukemia who have Down syndrome Journal of Pediatric Hematology/Oncology 18 10 12
11. Zubizarreta P. Felice M. Alfaro E. Fraquelli L. Casak S. Quinteros R. Cygler A. Gallego M. Perez L.E. Sackmann-Muriel F. 1998 Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy Leukemia Research 22 465 472
12. Zwaan C.M. Kaspers G. Pieters R. Hahlen K. Janka-Schaub G. van Zantwijk C. Huismans D. de Vries E. Rots M. Peters G. Jansen G. Creutzig U. Veerman A. 2002 Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome Blood 99 245 251